IMMUNE NETWORK

The Korean Association of Immunobiologists (대한면역학회)
권호 표지
DOI QR코드

DOI QR Code

Regulation of Inflammation by Bidirectional Signaling through CD137 and Its Ligand

  • Received : 2012.09.19
  • Accepted : 2012.10.12
  • Published : 2012.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Although the majority of research on CD137 has been directed to T cells, it is becoming clear that this molecule has distinct functions in other lineages of cells, including non-hematopoietic cells. In particular, emerging evidence suggests that the CD137-its ligand (CD137L) network involving immune cells and non-immune cells, directly or indirectly regulates inflammation in both positive and negative manners. Bidirectional signaling through both CD137 and CD137L is critical in the evolution of inflammation: 1) CD137L signaling plays an indispensible role in the activation and recruitment of neutrophils by inducing the production of proinflammatory cytokines and chemokines in hematopoietic and non-hematopoietic cells such as macrophages, endothelial cells and epithelial cells; 2) CD137 signaling in NK cells and T cells is required for their activation and can influence other cells participating in inflammation via either their production of proinflammatory cytokines or engagement of CD137L by their cell surface CD137: 3) CD137 signaling can suppress inflammation by controlling regulatory activities of dendritic cells and regulatory T cells. As recognition grows of the role of dysregulated CD137 or CD137L stimulation in inflammatory diseases, significant efforts will be needed to develop antagonists to CD137 or CD137L.

Keywords

References

  1. Medzhitov, R. 2008. Origin and physiological roles of inflammation. Nature 454: 428-435.
  2. Barton, G. M. 2008. A calculated response: control of inflammation by the innate immune system. J. Clin. Invest. 118: 413-420. https://doi.org/10.1172/JCI34431
  3. Seo, S. K., J. H. Choi, Y. H. Kim, W. J. Kang, H. Y. Park, J. H. Suh, B. K. Choi, D. S. Vinay, and B. S. Kwon. 2004. 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat. Med. 10: 1088-1094.
  4. Olofsson, P. S., L. A. Söderström, D. Wågsäter, Y. Sheikine, P. Ocaya, F. Lang, C. Rabu, L. Chen, M. Rudling, P. Aukrust, U. Hedin, G. Paulsson-Berne, A. Sirsjö, and G. K. Hansson. 2008. CD137 is expressed in human atherosclerosis and promotes development of plaque inflammation in hypercholesterolemic mice. Circulation 117: 1292-1301. https://doi.org/10.1161/CIRCULATIONAHA.107.699173
  5. Jeon, H. J., J. H. Choi, I. H. Jung, J. G. Park, M. R. Lee, M. N. Lee, B. Kim, J. Y. Yoo, S. J. Jeong, D. Y. Kim, J. E. Park, H. Y. Park, K. Kwack, B. K. Choi, B. S. Kwon, and G. T. Oh. 2010. CD137 (4-1BB) deficiency reduces atherosclerosis in hyperlipidemic mice. Circulation 121: 1124-1133. https://doi.org/10.1161/CIRCULATIONAHA.109.882704
  6. Dumitriu, I. E., P. Baruah, C. J. Finlayson, I. M. Loftus, R. F. Antunes, P. Lim, N. Bunce, and J, C, Kaski. 2012. High levels of costimulatory receptors OX40 and 4-1BB characterize CD4+CD28null T cells in patients with acute coronary syndrome. Circ. Res. 110: 857-869.
  7. Haga, T., J. Suzuki, H. Kosuge, M. Ogawa, H. Saiki, G. Haraguchi, Y. Maejima, M. Isobe, and T. Uede. 2009. Attenuation of experimental autoimmune myocarditis by blocking T cell activation through 4-1BB pathway. J. Mol. Cell. Cardiol. 46: 719-727. https://doi.org/10.1016/j.yjmcc.2009.02.003
  8. Seo, S. K., H. Y. Park, J. H. Choi, W. Y. Kim, Y. H. Kim, H. W. Jung, B. Kwon, H. W. Lee, and B. S. Kwon. 2003. Blocking 4-1BB/4-1BB ligand interactions prevents herpetic stromal keratitis. J. Immunol. 171: 576-583.
  9. Wang, J., Z. Guo, Y. Dong, O. Kim, J. Hart, A. Adams, C. P. Larsen, R. S. Mittler, and K. A. Newell. 2003. Role of 4-1BB in allograft rejection mediated by CD8+ T cells. Am. J. Transplant. 3: 543-551.
  10. Cho, H. R., B. Kwon, H. Yagita, S. La, E. A. Lee, J. E. Kim, H. Akiba, J. Kim, J. H. Suh, D. S. Vinay, S. A. Ju, B. S. Kim, R. S. Mittler, K. Okumura, and B. S. Kwon. 2004. Blockade of 4-1BB (CD137)/4-1BB ligand interactions increases allograft survival. Transpl. Int. 17: 351-361.
  11. Cheung, C. T., T. A. Deisher, H. Luo, B. Yanagawa, S. Bonigut, A. Samra, H. Zhao, E. K. Walker, and B. M. McManus. 2007. Neutralizing anti-4-1BBL treatment improves cardiac function in viral myocarditis. Lab. Invest. 87: 651-661.
  12. Kim, W., J. Kim, D. Jung, H. Kim, H. J. Choi, H. R. Cho, and B. Kwon. 2009. Induction of lethal graft-versus-host disease by anti-CD137 monoclonal antibody in mice prone to chronic graft-versus-host disease. Biol. Blood Marrow Transplant. 15: 306-314.
  13. Blazar, B. R., B. S. Kwon, A. Panoskaltsis-Mortari, K. B. Kwak, J. J. Peschon, and P. A. Taylor. 2001. Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus- leukemia, and graft rejection in allogeneic bone marrow transplant recipients. J. Immunol. 166: 3174-3183.
  14. Croft, M. 2009. The role of TNF superfamily members in T-cell function and diseases. Nat. Rev. Immunol. 9: 271-285.
  15. Kim, D. H., W. S. Chang, Y. S. Lee, K. A. Lee, Y. K. Kim, B. S. Kwon, and C. Y. Kang. 2008. 4-1BB engagement costimulates NKT cell activation and exacerbates NKT cell ligand- induced airway hyperresponsiveness and inflammation. J. Immunol. 180: 2062-2068.
  16. Vinay, D. S., B. K. Choi, J. S. Bae, W. Y. Kim, B. M. Gebhardt, and B. S. Kwon. 2004. CD137-deficient mice have reduced NK/NKT cell numbers and function, are resistant to lipopolysaccharide-induced shock syndromes, and have lower IL-4 responses. J. Immunol. 173: 4218-4229.
  17. Lee, S. C., S. A. Ju, H. N. Pack, S. K. Heo, J. H. Suh, S. M. Park, B. K. Choi, B. S. Kwon, B. S. Kim. 2005. 4-1BB (CD137) is required for rapid clearance of Listeria monocytogenes infection. Infect. Immun. 73: 5144-5151.
  18. Heinisch, I. V., I. Daigle, B. Knöpfli, and H. U. Simon. 2000. CD137 activation abrogates granulocyte-macrophage colony- stimulating factor-mediated anti-apoptosis in neutrophils. Eur. J. Immunol. 30: 3441-3446.
  19. Nishimoto, H., S. W. Lee, H. Hong, K. G. Potter, M. Maeda-Yamamoto, T. Kinoshita, Y. Kawakami, R. S. Mittler, B. S. Kwon, C. F. Ware, M. Croft, and T. Kawakami. 2005. Costimulation of mast cells by 4-1BB, a member of the tumor necrosis factor receptor superfamily, with the high-affinity IgE receptor. Blood 106: 4241-4248.
  20. Heinisch, I. V., C. Bizer, W. Volgger, and H. U. Simon. 2001. Functional CD137 receptors are expressed by eosinophils from patients with IgE-mediated allergic responses but not by eosinophils from patients with non-IgE-mediated eosinophilic disorders. J. Allergy Clin. Immunol. 108: 21-28.
  21. Futagawa, T., H. Akiba, T. Kodama, K. Takeda, Y. Hosoda, H. Yagita, and K. Okumura. 2002. Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int. Immunol. 14: 275-286.
  22. Wilcox, R. A., A. I. Chapoval, K. S. Gorski, M. Otsuji, T. Shin, D. B. Flies, K. Tamada, R. S. Mittler, H. Tsuchiya, D. M. Pardoll, and L. Chen. 2002. Cutting edge: Expression of functional CD137 receptor by dendritic cells. J. Immunol. 168: 4262-4267.
  23. Drenkard, D., F. M. Becke, J. Langstein, T. Spruss, L. A. Kunz-Schughart, T. E. Tan, Y. C. Lim, and H. Schwarz. 2007. CD137 is expressed on blood vessel walls at sites of inflammation and enhances monocyte migratory activity. FASEB J. 21: 456-463.
  24. Kim, C. S., J. G. Kim, B. J. Lee, M. S. Choi, H. S. Choi, T. Kawada, K. U. Lee, and R. Yu. 2011. Deficiency for costimulatory receptor 4-1BB protects against obesity-induced inflammation and metabolic disorders. Diabetes 60: 3159-3168.
  25. Lee, S. W., Y. Park, S. Y. Eun, S. Madireddi, H. Cheroutre,and M. Croft. 2012. Cutting edge: 4-1BB controls regulatory activity in dendritic cells through promoting optimal expression of retinal dehydrogenase. J. Immunol. 189: 2697- 2701.
  26. Kim, J., W. Kim, H. J. Kim, S. Park, H. A. Kim, D. Jung, H. J. Choi, S. J. Park, R. S. Mittler, H. R. Cho, and B. Kwon. 2012. Superscript CD25+CD4+Foxp3+ regulatory T cells primed by anti-CD137 mAbs inhibit graft-versus-host disease. Biol. Blood Marrow Transplant. 18: 44-54.
  27. Saiki, H., J. Suzuki, H. Kosuge, G. Haraguchi, T. Ishihara, T. Haga, Y. Maejima, M. Isobe, and T. Uede. 2008. Blockade of the 4-1BB pathway attenuates graft arterial disease in cardiac allografts. Int. Heart J. 49: 105-118.
  28. Kwon, B. 2009. CD137-CD137 Ligand Interactions in Inflammation. Immune Netw. 9: 84-89.
  29. Shao, Z. and H. Schwarz. 2011. CD137 ligand, a member of the tumor necrosis factor family, regulates immune responses via reverse signal transduction. J. Leukoc. Biol. 89: 21-29.
  30. Kim, D. K., S. C. Lee, and H. W. Lee. 2009. CD137 ligand- mediated reverse signals increase cell viability and cytokine expression in murine myeloid cells: involvement of mTOR/p70S6 kinase and Akt. Eur. J. Immunol. 39: 2617-2628.
  31. Kang, Y. J., S. O. Kim, S. Shimada, M. Otsuka, A. Seit-Nebi, B. S. Kwon, T. H. Watts, and J. Han. 2007. Cell surface 4-1BBL mediates sequential signaling pathways 'downstream' of TLR and is required for sustained TNF production in macrophages. Nat. Immunol. 8: 601-609.
  32. Kim, J. D., E. A. Lee, N. N. Quang, H. R. Cho, and B. Kwon. 2011. Recombinant TAT-CD137 ligand cytoplasmic domain fusion protein induces the production of IL-6 and TNF-$\alpha$ in peritoneal macrophages. Immune Netw. 11: 216-222.
  33. Kim, H. J., J. S. Lee, J. D. Kim, H. J. Cha, A. Kim, S. K. Lee, S. C. Lee, B. S. Kwon, R. S. Mittler, H. R. Cho, and B. Kwon. 2012. Reverse signaling through the costimulatory ligand CD137L in epithelial cells is essential for natural killer cell-mediated acute tissue inflammation. Proc. Natl. Acad. Sci. USA 109: E13-E22.
  34. Park, S. J., H. J. Kim, J. S. Lee, H. R. Cho, and B. Kwon. 2012. Reverse signaling through the co-stimulatory ligand, CD137L, as a critical mediator of sterile inflammation. Mol. Cells 33: 533-537.

Cited by

  1. Importance of reverse signaling of the TNF superfamily in immune regulation vol.9, pp.4, 2012, https://doi.org/10.1586/eci.13.14
  2. CD137-inducing factors from T cells and macrophages accelerate the destabilization of atherosclerotic plaques in hyperlipidemic mice vol.28, pp.11, 2014, https://doi.org/10.1096/fj.14-253732
  3. Substrate-dependent gene regulation of self-assembled human MSC spheroids on chitosan membranes vol.15, pp.1, 2012, https://doi.org/10.1186/1471-2164-15-10
  4. Integration of the Innate and Adaptive Immunity by CD137-CD137L Bidirectional Signals: Implications in Allograft Rejection vol.28, pp.3, 2012, https://doi.org/10.4285/jkstn.2014.28.3.113
  5. Tumor-Unrelated CD4 T Cell Help Augments CD134 plus CD137 Dual Costimulation Tumor Therapy vol.195, pp.12, 2012, https://doi.org/10.4049/jimmunol.1502032
  6. Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too? vol.16, pp.5, 2016, https://doi.org/10.1517/14712598.2016.1152256
  7. Genetic Aberrations Associated with Photodynamic Therapy in Colorectal Cancer Cells vol.20, pp.13, 2012, https://doi.org/10.3390/ijms20133254
  8. The Micro-Immunotherapy Medicine 2LEID Exhibits an Immunostimulant Effect by Boosting Both Innate and Adaptive Immune Responses vol.23, pp.1, 2022, https://doi.org/10.3390/ijms23010110